Farag A M, Bottoms S F, Mammen E F, Hosni M A, Ali A A, Moghissi K S
Department of Surgery, Wayne State University, Detroit, Michigan.
Obstet Gynecol. 1988 Apr;71(4):584-8.
We studied 30 control women and 131 pill users to evaluate effects of birth control pills and clinical factors on hemostasis. When control patients were matched with an equal number of pill users, none of the direct markers of activated hemostasis (fibrinopeptide A, platelet factor 4, and beta thromboglobulin) were increased. Plasminogen, prekallikrein, and protein C (protective against clotting) were significantly higher in pill users. Fibrinogen, antithrombin, alpha-2 antiplasmin, and fibronectin were comparable. Among the 131 pill users, antithrombin levels decreased with a family history of thromboembolism. Fibrinogen and fibronectin were increased with obesity, but there was no evidence of activated hemostasis. Overall, pill use did not appear to result in hypercoagulability. Considering family history of thromboembolism might further improve the safety of oral contraceptive use.
我们研究了30名对照女性和131名服用避孕药的女性,以评估避孕药和临床因素对止血的影响。当对照患者与相同数量的服药女性匹配时,激活止血的直接标志物(纤维蛋白肽A、血小板因子4和β-血小板球蛋白)均未升高。服用避孕药者的纤溶酶原、前激肽释放酶和蛋白C(抗凝血)水平显著更高。纤维蛋白原、抗凝血酶、α-2抗纤溶酶和纤连蛋白水平相当。在131名服用避孕药者中,有血栓栓塞家族史者抗凝血酶水平降低。纤维蛋白原和纤连蛋白水平随肥胖增加,但无激活止血的证据。总体而言,服用避孕药似乎不会导致高凝状态。考虑血栓栓塞家族史可能会进一步提高口服避孕药使用的安全性。